Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-24T13:34:30.220Z Has data issue: false hasContentIssue false
  • English
  • Français

Review of the International Society for Heart and Lung Transplantation Practice guidelines for management of heart failure in children*

Published online by Cambridge University Press:  17 September 2015

Steven D. Colan
Steven D. Colan*
Affiliation:
Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
*
Correspondence to: S. D. Colan, MD, Department of Cardiology, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, United States of America. Tel: +01 617 355 4886; Fax: +01 617 739 6282; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

In 2004, practice guidelines for the management of heart failure in children by Rosenthal and colleagues were published in conjunction with the International Society for Heart and Lung Transplantation. These guidelines have not been updated or reviewed since that time. In general, there has been considerable controversy as to the utility and purpose of clinical practice guidelines, but there is general recognition that the relentless progress of medicine leads to the progressive irrelevance of clinical practice guidelines that do not undergo periodic review and updating. Paediatrics and paediatric cardiology, in particular, have had comparatively minimal participation in the clinical practice guidelines realm. As a result, most clinical practice guidelines either specifically exclude paediatrics from consideration, as has been the case for the guidelines related to cardiac failure in adults, or else involve clinical practice guidelines committees that include one or two paediatric cardiologists and produce guidelines that cannot reasonably be considered a consensus paediatric opinion. These circumstances raise a legitimate question as to whether the International Society for Heart and Lung Transplantation paediatric heart failure guidelines should be re-reviewed.

The time, effort, and expense involved in producing clinical practice guidelines should be considered before recommending an update to the International Society for Heart and Lung Transplantation Paediatric Heart Failure guidelines. There are specific areas of rapid change in the evaluation and management of heart failure in children that are undoubtedly worthy of updating. These domains include areas such as use of serum and imaging biomarkers, wearable and implantable monitoring devices, and acute heart failure management and mechanical circulatory support. At the time the International Society for Heart and Lung Transplantation guidelines were published, echocardiographic tissue Doppler, 3 dimensional imaging, and strain and strain rate were either novel or non-existent and have now moved into the main stream. Cardiac magnetic resonance imaging (MRI) had very limited availability, and since that time imaging and assessment of myocardial iron content, delayed gadolinium enhancement, and extracellular volume have moved into the mainstream. The only devices discussed in the International Society for Heart and Lung Transplantation guidelines were extracorporeal membrane oxygenators, pacemakers, and defibrillators. Since that time, ventricular assist devices have become mainstream. Despite the relative lack of randomised controlled trials in paediatric heart failure, advances continue to occur. These advances warrant implementation of an update and review process, something that is best done under the auspices of the national and international cardiology societies. A joint activity that includes the International Society for Heart and Lung Transplantation, American College of Cardiology/American Heart Association, the Association for European Paediatric and Congenital Cardiology (AEPC), European Society of Cardiology, Canadian Cardiovascular Society, and others will have more credibility than independent efforts by any of these organisations.

Keywords

Heart failureguidelinespediatric
Type
Original Articles
Information
Cardiology in the Young , Volume 25 , Supplement S2: Special Supplement of Cardiology in the Young: Proceedings of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute , August 2015 , pp. 154 - 159
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Presented at Johns Hopkins All Children’s Heart Institute, International Pediatric Heart Failure Summit, Saint Petersburg, Florida, United States of America, 4–5 February, 2015.

References

1. Rosenthal, D, Chrisant, MR, Edens, E, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23: 1313–1333.Google Scholar
2. Jacobs, AK, Anderson, JL, Halperin, JL. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: 1373–1384.Google Scholar
3. Jacobs, AK, Kushner, FG, Ettinger, SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: 213–265.Google Scholar
4. Peterson, ED, Roe, MT, Mulgund, J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. J Am Med Assoc 2006; 295: 1912–1920.Google Scholar
5. Yancy, CW, Jessup, M, Bozkurt, B, et al. ACCF/AHA 2013 guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240–e327.Google Scholar
6. Kantor, PF, Lougheed, J, Dancea, A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 2013; 29: 1535–1552.Google Scholar
7. Gersh, BJ, Maron, BJ, Bonow, RO, et al. ACCF/AHA 2011 guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2761–2796.CrossRefGoogle Scholar
8. Elliott, PM, Anastasakis, A, Borger, MA, et al. ESC 2014 guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.Google Scholar
9. Shojania, KG, Sampson, M, Ansari, MT, Ji, J, Doucette, S, Moher, D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 2007; 147: 224–233.Google Scholar
10. Maron, BJ. Hypertrophic cardiomyopathy: a systematic review. J Am Med Assoc 2002; 287: 1308–1320.Google Scholar
11. Lang, RM, Bierig, M, Devereux, RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–1463.Google Scholar
12. Lipshultz, SE, Sleeper, LA, Towbin, JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 1647–1655.Google Scholar
13. Li, JS, Colan, SD, Sleeper, LA, et al. Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J 2011; 161: 233–240.Google Scholar
14. Lacro, RV, Dietz, HC, Sleeper, LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371: 2061–2071.Google Scholar
15. Silber, JH, Cnaan, A, Clark, BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820–828.CrossRefGoogle ScholarPubMed
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327: 685–691.Google Scholar
17. Kantor, PF, Rusconi, P, Lipshultz, S, Mital, S, Wilkinson, JD, Burch, M. Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: summary from the second international conference on pediatric cardiomyopathy. Prog Pediatr Cardiol 2011; 32: 11–14.Google Scholar
18. Hutchinson, LJ, Stuart, G, Walsh, MA. Implantation of the new Medtronic LINQ loop recorder in an infant with ventricular tachycardia. Cardiol Young 2014: 1–3.Google Scholar
19. Bui, AL, Fonarow, GC. Home monitoring for heart failure management. J Am Coll Cardiol 2012; 59: 97–104.Google Scholar
20. Vanderpluym, CJ, Fynn-Thompson, F, Blume, ED. Ventricular assist devices in children: progress with an orphan device application. Circulation 2014; 129: 1530–1537.Google Scholar
21. VanderPluym, C, Urschel, S, Buchholz, H. Advanced therapies for congenital heart disease: ventricular assist devices and heart transplantation. Can J Cardiol 2013; 29: 796–802.Google Scholar
22. Vanderpluym, CJ, Rebeyka, IM, Ross, DB, Buchholz, H. The use of ventricular assist devices in pediatric patients with univentricular hearts. J Thorac Cardiovasc Surg 2011; 141: 588–590.Google Scholar